renal cancer

In an AMP Global presentation, Danish Cancer Society Research Center scientists used the test to study urine samples from individuals who developed bladder cancer up to 15 years later.

In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.

A Baylor College of Medicine-led team uncovered nine genomic subtypes of kidney cancer that may help direct patients' treatments.

This Week in PNAS

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

Paradigm will use its NGS-based PCDx panel to characterize patient tissue samples in a phase I clinical study of altiratinib.

Cancer Genetics CEO Panna Sharma told GenomeWeb this week that the company plans to focus on very targeted panels of actionable mutations.

Researchers from the MD Anderson Cancer Center this month reported new data showing that the microRNA-200 family, which has previously been implicated in cancer metastasis, can regulate tumor angiogenesis.

NEW YORK (GenomeWeb News) – 23andMe today announced the expansion of its online study conducted with Genentech for the biotech firm's oncology drug Avastin (bevacizumab).

The companies' first project will be a renal cancer clinical trial for an undisclosed Quintiles client. The partners aim to identify genetic markers that are predictive of adverse events and efficacy.

Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."

Pages

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.